A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease

BACKGROUND: In Japan, selegiline has been approved for combination therapy with levodopa for Parkinson disease (PD). We conducted a trial of selegiline monotherapy for early PD. METHODS: In this 12-week controlled phase III trial, a total of 292 subjects were randomized to receive placebo (n = 146)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Neuropharmacol
Main Authors: Mizuno, Yoshikuni, Hattori, Nobutaka, Kondo, Tomoyoshi, Nomoto, Masahiro, Origasa, Hideki, Takahashi, Ryosuke, Yamamoto, Mitsutoshi, Yanagisawa, Nobuo
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5610558/
https://ncbi.nlm.nih.gov/pubmed/28857772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WNF.0000000000000239
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados